• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Tivic Health Systems Inc.

    7/25/25 4:56:51 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $TIVC alert in real time by email
    S-8 1 tivic_s8-handley.htm INITIAL REGISTRATION STATEMENT

    As filed with the Securities and Exchange Commission on July 25, 2025

     

    Registration No. 333-         

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    Tivic Health Systems, Inc.

    (Exact name of Registrant as specified in its charter)

     

    Delaware   81-4016391
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification Number)

     

    47685 Lakeview Blvd.

    Fremont, California 94538
    (888) 276-6888

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    Inducement Restricted Stock Unit Award

    (Full title of the plans)

     

    Jennifer Ernst
    Chief Executive Officer
    47685 Lakeview Blvd.

    Fremont, California 94538
    (888) 276-6888

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to:

     

    Christopher L. Tinen, Esq.

    Caitlin M. Murphey, Esq.
    Snell & Wilmer L.L.P.
    3611 Valley Centre Drive, Suite 500

    San Diego, CA 92130

    (858) 910-4809

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐   Accelerated filer ☐
    Non-accelerated filer ☒   Smaller reporting company ☒
          Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

       

     

     

    INTRODUCTION

     

    Tivic Health Systems, Inc. (the “Company,” “we,” “us,” or “our”) is filing this Registration Statement on Form S-8 (this “Registration Statement”) for the purpose of registering an aggregate of 35,295 shares of common stock of the Company, par value $0.0001 per share (“Common Stock”), issuable upon vesting and settlement of restricted stock units (“RSUs”) granted to Michael Handley, the Company’s Chief Operating Officer and President, Tivic Biopharma, on February 18, 2025 (the “Inducement Grant”). All share and per share data from the period prior to March 7, 2025 included in this Registration Statement has been retroactively adjusted to reflect the 1-for-17 reverse stock split of the Company’s issued and outstanding shares of Common Stock, which was effected on March 7, 2025.

     

    The Inducement Grant was granted outside of the Company’s Amended and Restated 2021 Equity Incentive Plan, as amended, as an inducement material to Mr. Handley entering into employment with the Company, was unanimously approved by both the Company’s Board of Directors (the “Board”) and Compensation Committee of the Board, and was issued pursuant to the “inducement” grant exception under Nasdaq Listing Rule 5635(c)(4).

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     2 

     

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(A) PROSPECTUS

     

    The information called for in Part I of Form S-8 to be contained in the Section 10(a) prospectus is not being filed with or included in this Registration Statement (by incorporation by reference or otherwise) in accordance with the rules and regulations of the Securities and Exchange Commission (the “Commission”). The documents containing the information specified in Part I of Form S-8 will be delivered to the recipient of the Inducement Grant covered by this Registration Statement, as specified by Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”).

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     3 

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents, which have been filed by the Company with the Commission pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated herein by reference:

     

      · the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 21, 2025 (the “Annual Report”);
         
      · the Company’s Quarterly Report on Form 10-Q filed with the Commission on May 15, 2025; and
         
      · the Company’s Current Reports on Form 8-K and 8-K/A filed with the Commission on January 3, 2025, February 5, 2025, February 12, 2025, February 24, 2025, March 5, 2025, March 6, 2025, March 21, 2025, April 3, 2025, April 10, 2025, April 14, 2025, April 22, 2025, May 2, 2025, May 14, 2025, May 20, 2025, June 25, 2025, July 7, 2025 and July 25, 2025 (provided that any portions of such reports that are deemed furnished and not filed pursuant to instructions to Form 8-K shall not be incorporated by reference into this prospectus); and
         
      · the description of the Company’s Common Stock contained in the Company’s Registration Statement on Form 8-A filed with the Commission on November 10, 2021 (File No. 001-41052), including any amendment or report filed for the purpose of updating such description, and Exhibit 4.4 of the Annual Report.

     

    All reports and other documents filed by the Company with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items, after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of filing such reports and documents.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Names Experts and Counsel.

     

    Not applicable.

     

     

     

     4 

     

     

    Item 6. Indemnification of Directors and Officers.

     

    As permitted by Section 102 of the Delaware General Corporation Law, we have adopted provisions in our amended and restated certificate of incorporation, as amended (“Charter”), and amended and restated bylaws, as amended (“Bylaws”), that limit or eliminate the personal liability of our directors for a breach of their fiduciary duty of care as a director. The duty of care generally requires that, when acting on behalf of the corporation, directors exercise an informed business judgment based on all material information reasonably available to them. Consequently, a director will not be personally liable to us or our stockholders for monetary damages for breach of fiduciary duty as a director, except for liability for:

     

    ·any breach of the director’s duty of loyalty to us or our stockholders;
       
    ·any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
       
    ·any act related to unlawful stock repurchases, redemptions or other distributions or payment of dividends; or
       
    ·any transaction from which the director derived an improper personal benefit.

     

    These limitations of liability do not affect the availability of equitable remedies such as injunctive relief or rescission. Our Charter authorizes us to indemnify our officers, directors and other agents to the fullest extent permitted under Delaware law.

     

    As permitted by Section 145 of the Delaware General Corporation Law, our Bylaws provide that:

     

    ·we may indemnify our directors, officers, and employees to the fullest extent permitted by the Delaware General Corporation Law, subject to limited exceptions;
       
    ·we may advance expenses to our directors, officers and employees in connection with a legal proceeding to the fullest extent permitted by the Delaware General Corporation Law, subject to limited exceptions; and
       
    ·the rights provided in our Bylaws are not exclusive.

     

    Our Charter provides that we will indemnify each person who was or is a party, or is or was threatened to be made a party, to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of us) by reason of the fact that he or she is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an “Indemnitee”), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful. Our Charter provides that we will indemnify any Indemnitee who was or is a party to an action or suit by or in the right of us to procure a judgment in our favor by reason of the fact that the Indemnitee is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys’ fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, except that no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to us, unless a court determines that, despite such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by us against all expenses (including attorneys’ fees) actually and reasonably incurred in connection therewith. Expenses must be advanced to an Indemnitee under certain circumstances.

     

     

     

     5 

     

     

    The above discussion of our Charter, Bylaws and Delaware law is not intended to be exhaustive and is respectively qualified in its entirety by such Charter, Bylaws and applicable Delaware law.

     

    We have entered into indemnification agreements with each of our directors and officers. These indemnification agreements may require us, among other things, to indemnify our directors and officers for certain expenses, including attorneys’ fees, judgments, fines and settlement amounts incurred by a director or officer in any action or proceeding arising out of his or her service as one of our directors or officers, or any of our subsidiaries or any other company or enterprise to which the person provides services at our request.

     

    We maintain standard policies of insurance that provide coverage for certain liabilities of directors and officers of our company arising out of claims based on acts or omissions in their capacities as directors or officers.

     

    To the extent that our directors and officers are indemnified under the provisions contained in our Charter, Bylaws, Delaware law or contractual arrangements against liabilities arising under the Securities Act, we have been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act, and is therefore unenforceable.

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

    Item 8. Exhibits.

     

    The exhibits to this Registration Statement are listed in the below Exhibit Index and are incorporated by reference herein.

     

    Exhibit
    Number
      Exhibit Description
    4.1   Amended and Restated Certificate of Incorporation of Tivic Health Systems, Inc., dated November 12, 2021 (incorporated by reference to Exhibit 3.1 to the Company’s Annual Report on Form 10-K, filed with the Commission on November 15, 2021).
    4.2   Amended and Restated Bylaws of Tivic Health Systems, Inc. (incorporated by reference to Exhibit 3.2 to the Company’s Annual Report on Form 10-K, filed with the Commission on November 15, 2021).
    4.3   Certificate of Amendment to the Amended and Restated Bylaws of Tivic Health Systems, Inc., dated July 5, 2023 (incorporated by reference to Exhibit 3.3 to the Company’s Annual Report on Form 10-K, filed with the Commission on July 6, 2023).
    4.4   Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Tivic Health Systems, Inc., filed August 21, 2023 (effective August 23, 2023) (incorporated by reference to Exhibit 3.4 to the Company’s Annual Report on Form 10-K, filed with the Commission on August 22, 2023).
    4.5   Certificate of Designation of Series A Non-Voting Convertible Preferred Stock of Tivic Health Systems, Inc., dated February 10, 2025 (incorporated by reference to Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q, filed with the Commission on May 15, 2025).
    4.6   Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Tivic Health Systems, Inc., filed March 4, 2025 (effective March 7, 2025) (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the Commission on March 5, 2025).
    4.7   Certificate of Designation of Series B Non-Voting Convertible Preferred Stock of Tivic Health Systems, Inc., dated April 29, 2025 (incorporated by reference to Exhibit 3.3 to the Company’s Quarterly Report on Form 10-Q, filed with the Commission on May 15, 2025).
    5.1*   Opinion of Snell & Wilmer L.L.P.
    23.1*   Consent of Rosenberg Rich Baker Berman, P.A.
    23.2*   Consent of Snell & Wilmer L.L.P. (included in Exhibit 5.1).
    24.1*   Power of Attorney (included on signature page).
    99.1*   Restricted Stock Unit Notice of Grant Inducement Grant and Restricted Stock Unit Award Agreement Inducement Grant, dated February 18, 2025.
    107*   Filing Fee Table.

     

    * Filed herewith

     

     

     6 

     

     

    Item 9. Undertakings.

     

    (a)The undersigned registrant hereby undertakes:

     

    (1)to file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i)to include any prospectus required by Section 10(a)(3) of the Securities Act;
       
    (ii)to reflect in the prospectus any facts or events arising after the effective date of this registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this registration statement;
       
    (iii)to include any material information with respect to the plan of distribution not previously disclosed in this registration statement or any material change to such information in this registration statement; provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this registration statement;

     

     provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.
       
    (2)that, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; and
       
    (3)to remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b)The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act that is incorporated by reference in this registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
       
    (c)Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     7 

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Fremont, State of California on July 25, 2025.

     

      TIVIC HEALTH SYSTEMS, INC.
       
      By: /s/ Jennifer Ernst
        Jennifer Ernst
        Chief Executive Officer

     

    POWER OF ATTORNEY

     

    Each person whose signatures appear below constitutes and appoints Jennifer Ernst and Lisa Wolf his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 to be filed by Tivic Health Systems, Inc., and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitutes, may lawfully do or cause to be done by virtue hereof.

     

    ***

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Jennifer Ernst   Chief Executive Officer   July 25, 2025
    Jennifer Ernst   (Principal Executive Officer)    
             
    /s/ Lisa Wolf   Chief Financial Officer   July 25, 2025
    Lisa Wolf    (Principal Financial and Accounting Officer)    
             
    /s/ Sheryle Bolton   Chair of the Board   July 25, 2025
    Sheryle Bolton        
             
    /s/ Christina Valauri   Director   July 25, 2025
    Christina Valauri        
             
    /s/ Dean Zikria   Director   July 25, 2025
    Dean Zikria        

     

     

     

     8 

    Get the next $TIVC alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $TIVC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TIVC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tivic Shareholders Approve Key Proposals in Support of Strategic Transformation; Lisa Wolf Appointed Permanent CFO

      Company provides additional management updates Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced that key proposals needed to carry out the company's strategic transformation were approved by shareholders at its annual meeting held on June 30, 2025. The approved proposals included the issuance of equity as a form of payment pursuant to Tivic's worldwide exclusive license agreement for Entolimod™ and Entolasta™, including for uses in acute radiation syndrome, neutropenia and other indications in oncology and hematology. Shareholders also approved the Company's issuance of equity in accordance with previously announced financing arrangeme

      7/8/25 8:30:00 AM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Tivic Health Completes Optimization Study for Its Non-Invasive Vagus Nerve Stimulation Device

      Breakthrough Findings to be Reported Later this Year and Applied to Upcoming Phase I Clinical Trial Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company developing treatments that stimulate immune pathways to treat disease, today announced it has completed all study visits in the Optimization Study for its patent pending, non-invasive cervical vagus nerve stimulation (ncVNS) device. Initial findings reinforce the importance of personalization for therapeutic efficacy. Tivic expects to release the study results later this year. The study was conducted by The Feinstein Institute of Bioelectronic Medicine with the objective of identifying device parameters th

      6/25/25 8:30:00 AM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Tivic Health Announces 2025 Annual Meeting of Stockholders

      Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, announced today its Virtual Annual General Meeting of Shareholders will be held on Monday, June 30, 2025 at 1:00 PM, Pacific Time | 4:00 PM Eastern Time. The Company has adopted a virtual format for its Annual Meeting to provide a consistent and convenient experience for all stockholders regardless of their location. In lieu of a live Q&A session, stockholders can submit questions for management's consideration through the virtual Annual Meeting platform both before and during the Annual Meeting. WHEN: Monday, June 30, 2025 TIME: 1:00 PM PT | 4:00 PM ET WHERE: w

      6/24/25 8:30:00 AM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $TIVC
    Leadership Updates

    Live Leadership Updates

    See more
    • Tivic Health Names Biotech Industry Veteran Michael K. Handley to Executive Leadership Team

      Handley Joins as President of Tivic Biopharma and Chief Operating Officer of Tivic Health Following Its Licensing of Strategic Biopharma Assets From Statera Biopharma Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, announced today that Michael K. Handley, formerly Chief Executive Officer, President and Chairman of Statera Biopharma, Inc., has joined Tivic Health as the President of Tivic Biopharma, a newly formed division of Tivic Health. Additionally, he will assume the role of Chief Operating Officer of Tivic Health and will work closely with the CEO and other leadership team members to develop and operationalize company-wide strategies. His key responsi

      2/24/25 8:15:00 AM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Tivic Health Appoints Lisa Wolf as Interim Chief Financial Officer

      Kimberly Bambach, Ms. Wolf's predecessor, continues with Tivic as advisor focused on strategic transactions and special projects Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, is pleased to announce the appointment of Lisa Wolf as Interim Chief Financial Officer (CFO) of the company, effective October 1, 2024. Ms. Wolf will take over from Kimberly Bambach, who has served as the company's interim CFO since April 2023. Ms. Bambach will continue with Tivic in an advisory role for strategic transactions and other special projects. "Lisa has served as a senior member of Tivic's finance team for over two

      9/13/24 5:29:00 PM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Tivic Announces Appointment of New Interim CFO, Kimberly Bambach, and Strategic Advisor to the Board, Christine Valauri

      Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced the appointment of veteran Kimberly Bambach to serve as Interim Chief Financial Officer of the company and the engagement of Christina Valauri as a strategic advisor to the Board of Directors. These additions aim to strengthen the company's financial foundation and bring growth and M&A expertise to the team. Ms. Bambach brings over 30 years of financial leadership experience in both public and private companies across industries. Her background includes financial leadership in medical and retail markets, manufacturing, wholesale distrib

      5/1/23 9:30:00 AM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $TIVC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Operating Officer Handley Michael K

      4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

      2/24/25 5:01:03 PM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 3 filed by new insider Handley Michael K

      3 - Tivic Health Systems, Inc. (0001787740) (Issuer)

      2/24/25 5:00:08 PM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Director Valauri Christina Rizopoulos

      4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

      12/20/24 5:15:03 PM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $TIVC
    SEC Filings

    See more
    • Amendment: SEC Form S-1/A filed by Tivic Health Systems Inc.

      S-1/A - Tivic Health Systems, Inc. (0001787740) (Filer)

      7/25/25 5:04:04 PM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form S-8 filed by Tivic Health Systems Inc.

      S-8 - Tivic Health Systems, Inc. (0001787740) (Filer)

      7/25/25 4:56:51 PM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form S-8 filed by Tivic Health Systems Inc.

      S-8 - Tivic Health Systems, Inc. (0001787740) (Filer)

      7/25/25 4:55:44 PM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $TIVC
    Financials

    Live finance-specific insights

    See more
    • Tivic Reports First Quarter 2025 Financial Results and Provides Updates on Business Transformation

      Pre-recorded Conference Call to Follow at 1:30 p.m. PDT/4:30 p.m. EDT Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced financial results for the first quarter ended March 31, 2025 and outlined operational highlights based on its newly expanded clinical pipeline. "This is a defining time for the company. During the quarter we initiated a significant strategic shift, dramatically expanding Tivic's clinical pipeline for restoring immune system health," stated Tivic CEO Jennifer Ernst. "In February, we executed a comprehensive worldwide exclusive licensing agreement for the Phase III TLR5 agonist, Entolimod and its molecular derivative, Ent

      5/15/25 4:05:00 PM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Tivic Health to Report First Quarter 2025 Financial Results on May 15th Via Conference Call and Webcast

      Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health, today announced that it will report its first quarter results for 2025 via pre-recorded conference call and webcast on Thursday, May 15, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 1-877-407-0779 International: 1-201-389-0914 Conference ID: 13753498 Webcast Link https://viavid.webcasts.com/starthere.jsp?ei=1717125&tp_key=322c3ca4f6 About Tivic Health Systems, Inc. Tivic Health is a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight

      5/9/25 8:30:00 AM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Tivic Reports Year End 2024 Financial Results and Provides Overview of Strategy for Transformation and Growth

      Pre-recorded Conference Call and Webcast to Follow Today at 1:30 PM PDT / 4:30 PM EDT Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, today announced year end December 31, 2024 financial results, highlighted key developments in its clinical program expansion and discussed progress made across the company's operations. "The important strategic events of the past several months have been nothing short of transformative," stated Tivic Health Chief Executive Officer, Jennifer Ernst. "We have successfully reshaped the company by expanding Tivic's opportunities in the biotech sector by in-licensing a late-stage biologic immunotherapy and advancing our ongoing work

      3/21/25 4:00:00 PM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $TIVC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Tivic Health Systems Inc.

      SC 13G - Tivic Health Systems, Inc. (0001787740) (Subject)

      5/15/24 4:47:23 PM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Tivic Health Systems Inc. (Amendment)

      SC 13G/A - Tivic Health Systems, Inc. (0001787740) (Subject)

      2/9/24 4:05:08 PM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Tivic Health Systems Inc. (Amendment)

      SC 13G/A - Tivic Health Systems, Inc. (0001787740) (Subject)

      2/1/24 9:01:29 AM ET
      $TIVC
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care